Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2022 | Story André Damons | Photo André Damons
UFS Nuclear Medicine
The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment. 

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.


Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”


“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.” 

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

 

News Archive

UFS Physics Research Chair receives more funding
2017-11-20


 Description: Prof Hendrik Swart, Physics Research Chair receives more funding Tags: Prof Hendrik Swart, Physics Research Chair receives more funding

Prof Hendrik Swart, Senior Researcher Professor in the
Department of Physics at UFS.
Photo: Charl Devenish

A research project into low-energy lighting using phosphor materials for light emitting diodes (LEDs) at the Department of Physics at the University of the Free State (UFS) has received further recognition. 

The South African Research Chairs Initiative (SARChi) has awarded further funding for the Research Chair in Solid State Luminescent and Advanced Materials situated in the department. Prof Hendrik Swart, a Senior Research Professor in the Department of Physics, says this means that the Chair will carry on receiving funds from SARChi for another five years. The Initiative also awarded Prof Swart in 2012 for the research, which resulted in funding for equipment and among others, bursaries.    

Better light emission in LED’s
The research focuses on better light emission of phosphor powers in LEDs. It is also looking into improving LED displays in flat screens. The research into solar cells has shown that phosphors can also increase their efficiency by increasing the range of light frequencies, which convert into electricity. It also entails that glow-in-the-dark coatings absorb light during the day and emit it at night. 

Prof Swart says over the next five years the research will focus on developing and producing devices that emit better light using the substances already developed. “We need to make small devices to see if they are better than those we already have.” In practical terms, it means they want a farmer’s water pump that works with solar energy to work better with less energy input.” 

Device that simulates sunlight
Prof Swart says the renewal of the Chair’s funding means the department can now get equipment to enhance its research   such as a solar simulator. The solar simulator uses white LEDs whose intensity output and wavelengths can be tuned. The output is measured in number of suns. It enables researchers to work in a laboratory with a device that simulates sunlight.     

According to Prof Swart the long-term benefit of the research will result in more environmentally friendly devices which use less energy, are brighter and give a wider viewing field. 

About 10 postdoctoral researchers are working on the studies done by the Chair in collaboration with the Council for Scientific and Industrial Research. 

The Research Chair Initiative aims to improve the research capacity at public universities to produce high-quality postgraduate students, research and innovative outputs. The criterion for evaluating the department’s Chair includes aspects such as how much development has occurred over the past five years. The assessors look at features such as the number of students the research entity has trained and how many publications the research team has produced.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept